Specifically, when WT1 overexpression is added to the predefined risk groups, it may increase the risk or abridge the favorable outcome of the CN-AML patients by interactions with the favorable group or with the unfavorable group, respectively. Here, WT1 is linked to acute myeloid leukemia.